Keros Therapeutics KROS 深 沪
等待开盘 04-02 09:30:00 美东时间
11.69
+0.650
+5.89%
华盛通- 最 高11.96
- 今 开11.10
- 成交量 60.60万股
- 最 低 11.08
- 昨 收 11.04
- 总市值 2.30亿
- 52周最高 22.55
- 市盈率 静 5.09
- 换手率 3.07%
- 52周最低 10.415
- 委 比 86.37%
- 总股本 1971.75万
- 历史最高 88.80
- 量 比 1.56
- 振 幅 7.97%
- 历史最低 9.12
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
03-10 18:41
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
Keros Therapeutics ( ($KROS) ) has shared an update. On March 9, 2026, Keros Th...
03-09 20:32
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.
03-06 00:36
Keros Therapeutics: Q4 Earnings Insights
The Q4 earnings report for Keros Therapeutics (NASDAQ:KROS) was released on Wed...
03-05 05:18
Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $3.042M Beat $2.757M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses of $(1.14) per share
03-05 05:04
Keros Therapeutics CEO to Present at Multiple Conferences
Keros Therapeutics ( ($KROS) ) has shared an announcement. On February 18, 2026...
02-19 06:20
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics' CEO, Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in February and March 2026. The presentations include Oppenheimer's 36th Annual Healthcare Life Sciences Conference on February 25, TD Cowen's 46th Annual Health Care Conference on March 3, and Leerink Partners' Global Healthcare Conference on March 10. All sessions will be available for replay on Keros' investor website for 90 days post-event. Keros fo...
02-18 21:01
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19
B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $18 to $19.
2025-11-29 01:08
